Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
OVID · Why this verdict
Why Ovid Therapeutics (OVID) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Ovid Therapeutics is a cash-burning, near-pre-revenue biotech with large analyst-implied upside and a pullback within a rising trend, but quality is below the floor and leverage is flagged as high.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The $5.22 analyst target sits 141.7% above the $2.16 price (raw analyst upside 178%), with reward-to-risk of 9.4 against 15% downside. Upside pct | Price moves toward the analyst target as pipeline milestones and financing events play out over 12 months. | →Stable |
| CounterCoverage is light (dampened signal) and biotech targets depend on binary trial outcomes, so a single failure could make the target irrelevant. | ||
Quality notes flag cash-burning with FCF at -2092% of revenue and a Rule of 40 reading of -2181, against quarterly revenue of only $733K. Quality breakdown | Cash burn continues, and the company needs funding or partnership revenue within 12 months. | →Stable |
| CounterRevenue is lumpy (quarterly revenue reached $6.27M in June 2025), so a single collaboration payment could change the picture quickly. | ||
The stock is below its 200-day average, but that average is still rising 5.5% per 30 days and OBV shows accumulation, a pullback in an uptrend rather than confirmed weakness. Momentum breakdown | Price retakes the 200-day moving average while OBV keeps rising over the next two quarters. | ↓Deteriorating |
| CounterThe RSI component is weak and implied volatility is 141%, so a sharp move down is as likely as a recovery. | ||
Over the last 4 quarters Ovid posted 2 beats, 1 inline and 1 miss, with the latest loss of $0.08 per share better than the $0.10 loss estimate. Earnings | Quarterly losses stay at or below consensus estimates, including the report due in 18 days. | →Stable |
| CounterThe beats are small beats on losses, and the March 2026 positive EPS of $0.06 looks like a one-time item rather than a trend. | ||
Warnings flag value-trap signals (2/5): high leverage (D/E 3.1) and material insider selling (50 sells, 0.72% of market cap), with quality at 3.1. Warnings | Leverage stays elevated and quality stays below the 4.0 floor until revenue grows. | ↑Improving |
| CounterRecent insider data shows no net activity in the last 90 days and institutions are accumulating, which weakens the insider-selling signal. | ||
The $5.22 analyst target sits 141.7% above the $2.16 price (raw analyst upside 178%), with reward-to-risk of 9.4 against 15% downside.
→StableUpside pct
- Expectation
- Price moves toward the analyst target as pipeline milestones and financing events play out over 12 months.
CounterCoverage is light (dampened signal) and biotech targets depend on binary trial outcomes, so a single failure could make the target irrelevant.
Quality notes flag cash-burning with FCF at -2092% of revenue and a Rule of 40 reading of -2181, against quarterly revenue of only $733K.
→StableQuality breakdown
- Expectation
- Cash burn continues, and the company needs funding or partnership revenue within 12 months.
CounterRevenue is lumpy (quarterly revenue reached $6.27M in June 2025), so a single collaboration payment could change the picture quickly.
The stock is below its 200-day average, but that average is still rising 5.5% per 30 days and OBV shows accumulation, a pullback in an uptrend rather than confirmed weakness.
↓DeterioratingMomentum breakdown
- Expectation
- Price retakes the 200-day moving average while OBV keeps rising over the next two quarters.
CounterThe RSI component is weak and implied volatility is 141%, so a sharp move down is as likely as a recovery.
Over the last 4 quarters Ovid posted 2 beats, 1 inline and 1 miss, with the latest loss of $0.08 per share better than the $0.10 loss estimate.
→StableEarnings
- Expectation
- Quarterly losses stay at or below consensus estimates, including the report due in 18 days.
CounterThe beats are small beats on losses, and the March 2026 positive EPS of $0.06 looks like a one-time item rather than a trend.
Warnings flag value-trap signals (2/5): high leverage (D/E 3.1) and material insider selling (50 sells, 0.72% of market cap), with quality at 3.1.
↑ImprovingWarnings
- Expectation
- Leverage stays elevated and quality stays below the 4.0 floor until revenue grows.
CounterRecent insider data shows no net activity in the last 90 days and institutions are accumulating, which weakens the insider-selling signal.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -2092% of revenue
- ▸Rule of 40: -2181 (fail)
Growth
5.0/10data confidence 50%Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 6.4 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 4.4 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 161%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.7 |
| growth rank | 0.5 |
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.9 |
| support resistance | 3.6 |
| 52w position | 5.8 |
Risk (lower is worse)
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.7 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 9.8 |
- ▸High IV: 143%
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings in 12 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.7>=5.5
- ASYMMETRY:8.5>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:12d<=14d (soft)
Reward-to-Risk
8.48
Upside
+127.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 8.48.
The strongest dimensions are Value at 9.0, Sentiment at 7.9, and Insider at 7.3; the weakest are Quality at 3.1, Technical at 3.8, and Peer rank at 4.1. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 8.48 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Upside
Trip ifAnalyst target falls below $2.80, less than 30% above the current $2.16 price.
- P2Severe Cash Burn
Trip ifQuarterly revenue exceeds $10M, ending the cash-burning profile.
- P3Pullback In Rising Trend
Trip ifThe 30-day change in the 200-day moving average falls below 0% from current +5.5%.
- P4Improving But Uneven Earnings
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P5Leverage And Insider Selling Flags
Trip ifDebt-to-equity falls below 1.5 from current 3.1 and quality score rises above 4.0.